1. Home
  2. BNL vs NAMS Comparison

BNL vs NAMS Comparison

Compare BNL & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Broadstone Net Lease Inc.

BNL

Broadstone Net Lease Inc.

HOLD

Current Price

$19.65

Market Cap

3.8B

Sector

Real Estate

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$35.17

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNL
NAMS
Founded
2007
2019
Country
United States
Netherlands
Employees
N/A
100
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
3.5B
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
BNL
NAMS
Price
$19.65
$35.17
Analyst Decision
Buy
Strong Buy
Analyst Count
9
8
Target Price
$20.22
$46.75
AVG Volume (30 Days)
3.5M
793.0K
Earning Date
04-29-2026
05-07-2026
Dividend Yield
5.87%
N/A
EPS Growth
N/A
N/A
EPS
0.50
N/A
Revenue
$454,138,000.00
N/A
Revenue This Year
$7.99
$17.96
Revenue Next Year
$5.27
$540.65
P/E Ratio
$39.81
N/A
Revenue Growth
5.17
N/A
52 Week Low
$15.28
$15.70
52 Week High
$19.91
$42.00

Technical Indicators

Market Signals
Indicator
BNL
NAMS
Relative Strength Index (RSI) 60.39 62.96
Support Level $18.56 $34.05
Resistance Level $19.82 $37.43
Average True Range (ATR) 0.39 1.68
MACD 0.14 0.57
Stochastic Oscillator 85.64 91.96

Price Performance

Historical Comparison
BNL
NAMS

About BNL Broadstone Net Lease Inc.

Broadstone Net Lease Inc is an internally managed real estate investment trust that invests in, owns, and manages single-tenant commercial real estate properties that are net leased on a long-term basis to a diversified group of tenants. The company has selectively invested in net leased assets in the industrial, healthcare, restaurant, retail, and office property types. The company focuses on investing in real estate that is operated by creditworthy single tenants in industries characterized by positive business drivers and trends. The company targets properties that are an integral part of the tenants' businesses and are therefore opportunities to secure long-term net leases.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: